WestGene

Exciting news! We're delighted to announce that we will be presenting our latest research at ESMO Congress 2024. Join us as we share findings from our exploratory study of the safety, immunogenicity and preliminary anti-tumour activity of the EBV mRNA vaccine (WGc-043 injection) in patients with NK/T cell lymphoma. Date: Sunday, 15 September 2024 Time: 08:40 - 08:45 AM  Location: Oviedo Auditorium - Hall 3 We look forward to meeting fellow researchers and professionals in the field to discuss the potential of mRNA therapeutics in oncology. See you there! #ESMO #ESMO2024 #oncology #mRNA #NKTCL

Dr. Xiangrong Song, General Manager and co-founder of WestGene Biopharma, will attend the 4th mRNA-Based Therapeutics Summit in Boston. Dr Song will present WestGene's groundbreaking mRNA platform and showcase our latest advances in the treatment of cancer. Join us as she shares valuable insights into the proven safety and efficacy of our mRNA-based therapeutics and highlights the transformative potential of mRNA technology in the fight against cancer. https://ter.li/zighu1

WestGene is here at BIO 2024! We welcome all interested parties to contact us to discuss potential collaboration opportunities. Let's explore how we can work together to advance mRNA therapeutics. Collaboration Opportunities: We are open to collaborations on our pipeline, including our IND-approved EBV-related cancer vaccine WGc-043, which has demonstrated superior safety and efficacy. In addition, we have promising data for our liver cancer vaccine WGc-0201 and preclinical programs targeting multiple solid tumors. We also welcome co-development opportunities utilizing our mature mRNA technology for targeted indications, protein replacement and other innovative collaborations. We look forward to meeting and exploring potential partnerships at BIO 2024! Please feel free to contact us to schedule a meeting. #BIO2024 #BIO #mRNA

🎉 Exciting news! 🎉 Our mRNA therapeutic cancer vaccine, WGc-043, has just received FDA IND approval! It's a game changer in cancer treatment. Let's work together to make a difference! The FDA approval of WGc-043 represents a significant advance in cancer treatment and offers new hope for patients with advanced EB virus-related cancers. WGc-043 demonstrates promising efficacy, low toxicity, broad applicability, efficient scalability and cost effectiveness. WGc-043 has already completed investigator-initiated trials (IIT) in NPC and NKTL, demonstrating superior safety and efficacy compared to other publicly available mRNA therapeutic cancer vaccines. read more: https://lnkd.in/ezuBUrhm #FDAApproval #IND #EBV #mRNA #CancerVaccine #CollaborateWithUs